About Strides Shasun Ltd.



Strides Shasun Limited is an Indian pharmaceutical company headquartered in Bengaluru, Karnataka, India. It was formed in 2015 after the merger of two companies, Shasun Pharmaceuticals and Strides Arcolab. The company manufactures and sells active pharmaceutical ingredients (APIs), pharma and branded generics, nutraceuticals and bio-generic products in 85+ countries, including India, USA, Europe and Africa.


As per Strides Shasun’s Annual Report for the FY 2015-16, it had:


  • 14 manufacturing facilities (5 in India; 7 in Africa, 1 in Italy and 1 in UK), comprising:
    • 6 US FDA approved facilities
    • 8 facilities for emerging markets
  • 3 R&D facilities employing 400+ scientists
  • Invested approx. 2.38% of its 2015-16 sales turnover on Research & Development


Strides Shasun Limited is listed on the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE).


Strides Shasun Limited at-a-glance* (as of 31st March 2016)


  • Employees 5500+
  • Turnover (31 March, 2016) ~USD 479+ million
    (? 31,776 million)
  • International Footprint 85+ countries
  • Major Markets USA, Europe, Africa, India
  • Manufacturing Facilities 14
  • R&D Centers 3
  • ANDAs Filed (2015-16) 52
  • ANDAs Pending Approval 29










Health Canada



Annual Report 2015-16




Strides Shasun Limited was formed after the merger of Shasun Pharmaceuticals with Strides Arcolab on 19th November, 2015.


Prior to the 2015 merger:


  • Strides Arcolab (incorporated in 1990) was headquartered in Bengaluru, India with a key focus on the development of niche generics and bio-pharmaceuticals.
  • Shasun Pharmaceuticals Limited (incorporated in 1976) was headquartered in Chennai, and developed and manufactured intermediates, APIs (Active Pharmaceutical Ingredients) and Formulations.






  • 1976-77 – Shasun Pharmaceuticals is incorporated in Chennai, and its first production facility is setup for Analgin
  • 1986 – Shasun Pharmaceuticals sets up second manufacturing facility at Pondicherry for Ibuprofen
  • 1990 – Strides Pharmaceuticals is established in Vashi, New Bombay


  • 1991Shasun Pharmaceuticals sets up third manufacturing facility in Cuddalore for manufacturing Ranitidine HCl
  • 1992 – Strides Pharmaceuticals starts exporting to Nigeria
  • 1992 – Shasun Pharmaceuticals establishes US subsidiary
  • 1994 – Shasun Pharmaceuticals raises approx. ?6 crore via initial public offering (IPO)
  • 1994 – Strides Pharmaceuticals receives venture capital funding from Schroders
  • 1995 – Strides Pharmaceuticals:
    • sets up new sterile manufacturing facility in Bengaluru
    • establishes soft gelatin capsule plant
  • 1996 – Strides Pharmaceuticals:
    • changes its name to Strides Arcolab Limited
    • acquires a bulk drug facility in Mangalore (Plama Laboratories Limited)
  • 1999 – Strides Arcolab:
    • enters LATAM market via investments in Infabra, Brazil
    • acquires Remed Laboratories
    • acquires Global Remedies Limited (Hosur, Tamil Nadu)
    • Merges Plama Laboratories and Remed Laboratories with Strides Arcolab
  • 2000 – Strides Arcolab:
    • is listed on the National Stock Exchange (NSE)
    • acquires soft gelatin facility in the US
  • 2001 – Strides Arcolab acquires Bombay Drugs & Pharmas Limited
    (with manufacturing facilities in Tarapur, Maharashtra and Panoli, Gujarat
  • 2002 – Strides Arcolab:
    • is listed on the Bombay Stock Exchange
    • acquires a stake in Solara, Mexico
    • sets up manufacturing plants in Brazil and Mexico
  • 2003 – Strides Arcolab commences development and manufacture of drugs against AIDS, TB and Malaria
  • 2004 – Strides Arcolab enters a joint venture with Akorn Inc. to penetrate the US hospital market for sterile products
  • 2005 – Strides Arcolab inaugurates the global research and development centre, Star Technology and Research (STAR) in Bengaluru
  • 2005 – Shasun Pharmaceuticals commissions new Research Centre and Formulations facility
  • 2006 – Strides Arcolab:
    • enters an alliance with the Clinton Foundation for supplying AIDS drugs
  • acquires ICN Valeant Sterile's manufacturing unit in Poland
  • acquires a controlling stake in Beltapharm SpA in Italy
  • acquires Drug Houses of Australia (Asia) Pte Limited, Singapore
  • enters a joint venture with Invent Farma in Spain (for Spanish and Portuguese markets)
  • 2006 – Shasun Pharmaceuticals successfully completes acquisition of Rhodia Pharma Solutions
  • 2007 – Strides Arcolab:
  • forms a joint venture with Sagent Pharmaceuticals for specialty products in USA
  • acquires Grandix (a leading brand marketing company) to enter the domestic Indian market
  • buys 100% ownership of Farma Plus AS in Norway
  • cedes 50% ownership in LATAM operations to Aspen Group
  • forms a joint venture with Aspen Group to set up an Oncology facility in India
  • 2008 – Strides Arcolab:
  • enters a licensing deal with GlaxoSmithKline Pharmaceuticals for distribution in over 95 countries
  • acquires controlling stake in Ascent PharmaHealth, an AXS listed company and a major generics player in Australia
  • 2009 – Strides Arcolab:
  • launches Ray of Life, a critical care division with a portfolio of specialty products
  • launches Starflu to treat H1N1
  • 2009 – Shasun Pharmaceuticals launches recombinant streptokinase in India
  • 2010 – Strides Arcolab:
  • collaborates with Pfizer to license and supply 40 off–patent products for the US market
  • buys Campos facility in Brazil from Aspen
  • extends Pfizer transaction to cover Canada, Australia, European Union, Japan, New Zealand and Korea
  • rebrands Specialty Division as Agila Specialties Private Limited
  • acquires biotechnology company (Inbiopro Solutions) to enter the biologics space
  • 2010 – Shasun Pharmaceuticals’ finished dosages sales grow by 100% to reach ?50 crores
  • 2011 – Strides Arcolab files 31 ANDAs during the year and receives 27 approvals, taking total ANDA filings to 183 and total approvals to 79
  • 2011 – Shasun Pharmaceuticals:
  • forms 50:50 JV NBI LLC (USA) with Nanoparticle Biochem

  • expands Formulations facility to 5 billion OSD

  • 2012 – Strides Arcolab:
  • sells off generic pharmaceuticals operations in Australia and SE Asia (Ascent) to Watson Pharmaceuticals for AUD 375 million
  • acquires a USFDA approved sterile formulations facility in Hosur, Tamilnadu, India from Star Drugs for ?1250 million via Agila
  • enters Canadian sterile space via marketing joint venture with Canadian generic drug company, Jamp Pharma
  • collaborates with GILEAD Sciences, Inc. to promote access to high-quality, low-cost generic versions of their HIV medicines in developing markets
  • 2012 – Shasun Pharmaceuticals:
  • records a milestone turnover of ?1000 crores
  • expands formulation capacity to USD 5 billion
  • 2013 – Strides Arcolab:
  • enters agreement with Mylan Inc to sell off Agila Specialties division for USD 1.6 billion plus USD 250 million
  • consolidates stake in Inbiopro Solutions Pvt. Ltd. from 70% to 100% to become a 100% subsidiary of Strides
  • enters a JV with Pfenex Inc. CA, USA (via Agila Biotech) to develop, manufacture and commercialize an initial pipeline of 6 bio-similars
  • 2013 – Shasun Pharmaceuticals receives:
  • 2012 NEPIC UK Award for innovation
  • Silver Award from Pharmaexil for highest export in the large-scale category
  • 2014 – Shasun Pharmaceuticals:
  • forms a Joint Venture with Alivira Animal Health Ltd
  • acquires global rights of Nuprina brand
  • undergoes successful completion of US FDA, Brazilian ANVISA and MHRA EU inspection at SPSL, UK




  • Chairman Deepak Vaidya
  • Executive Vice Chairman & Managing Director Arun Kumar
  • Executive Director Abhaya Kumar
  • Independent Directors S Sridhar, AK Nair, PM Thampi, Sangita Reddy, Bharat Shah
  • Non-Executive Director MR Umarji





Strides Limited
Strides House, Bilekahalli

Bannerghatta Road
Bengaluru – 560 076



Website: www.stridesarco.com  

Tel: +91 80 6784 0000 / 6784 0738
Fax: +91 80 6784 0700 / 6784 0800

E mail:  info@strides.com



201, Devavrata, Sector 17
Vashi, Navi Mumbai – 400 703



Tel: +91 22 2789 2924/ 2789 3199
Fax: +91 22 2789 2942
E mail:  info@strides.com





3 Tuas South Avenue 4,

Singapore – 637610


Level 18, 530 Collins Street,

Melbourne, Vic 3000


No.43-A, Street No.420,

Sangkat Boeung Trabek

Khan Chamkarmon, Phnom Penh,



S/C B.P 2353 Douala AKWA

Rue DUBOIS De Saligny



Unit 1010, Antel Global

Corporate Centre,

Julia Vargas Avenue, Ortigas

Central Business District,

Metro Manila

Pasig City 1605


No.104, 1/3, Pagoda Road,

Pitakotte - 10100,

Colombo, Sri Lanka


Rue Fritz-Cournvoisier 40

2300 La Chaux-De-Fonds

Suisse, Switzerland



Unit 4, Metro Centre, Tolpits Lane,

Watford, Hertfordshire,

WD18 9SS, UK


Dudley Lane, Dudley,

Cramlington, Northumberland,

England NE 237QG


2 Tower Center Blvd.,

Suite: 1102

East Brunswick, NJ 08816.


197, Rt 18 South, Suite 102,

East Brunswick, NJ 08816




* Indicates mandatory field.
Please wait while comments are being sent...